Which orexin‑2 receptor antagonist has the greatest efficacy for insomnia according to the literature?

Orexin Receptor Antagonist Efficacy for Insomnia

Among orexin receptor antagonists, lemborexant 10 mg demonstrates the greatest efficacy for reducing wake after sleep onset (WASO), while suvorexant remains the only agent with formal guideline endorsement from the American Academy of Sleep Medicine.

Guideline-Based Recommendations

The 2017 American Academy of Sleep Medicine (AASM) clinical practice guideline provides a weak recommendation for suvorexant (10,15/20, and 20 mg doses) as treatment for sleep maintenance insomnia in adults 1. This is currently the only orexin receptor antagonist with formal guideline support, as it was the only agent available at the time of guideline publication 1.

Key Efficacy Data from Guidelines:

• Suvorexant reduces WASO by 16-28 minutes compared to placebo (95% CI: 7 to 43 minutes) 1
• Total sleep time improves by 10 minutes (95% CI: 2 to 19 minutes) 1
• Sleep efficiency improvements are near or above clinical significance thresholds 1
• The quality of evidence was rated as low due to imprecision and potential publication bias 1

Comparative Efficacy: Recent Meta-Analyses

Lemborexant Shows Superior WASO Reduction

A 2025 systematic review and meta-analysis directly comparing lemborexant and daridorexant found that lemborexant was more effective than daridorexant for key sleep parameters 2:

• WASO reduction: Lemborexant achieved -45.15 minutes (95% CI: -51.75 to -38.56) versus daridorexant's -12.6 minutes (95% CI: -18.71 to -6.5) 2
• Subjective sleep onset latency (sSOL): Lemborexant reduced sSOL by -25.01 minutes (95% CI: -28.58 to -21.44) compared to daridorexant's -2.33 minutes (95% CI: -7.1 to 2.45, not statistically significant) 2

Network Meta-Analysis Findings

A 2023 network meta-analysis of 10 RCTs (7,806 patients) evaluating all dual orexin receptor antagonists (DORAs) confirmed 3:

• Lemborexant 10 mg provided the largest WASO reduction at month 1: -25.40 minutes (95% CI: -40.02 to -10.78) 3
• Suvorexant 20/15 mg showed comparable short-term WASO reduction: -25.29 minutes (95% CI: -36.42 to -14.15) 3
• Suvorexant 20/15 mg appeared superior for long-term WASO reduction: -23.70 minutes (95% CI: -35.89 to -11.51) 3
• A dose-dependent pattern was observed for total sleep time across all DORAs 3

Selective OX2 Receptor Antagonists

Seltorexant (OX2-Selective)

A 2018 Phase 2 study of seltorexant 40 mg (selective OX2 receptor antagonist) demonstrated 4:

• Sleep efficiency increased by 5.8% (single dose) and 7.9% (Day 5) compared to placebo (p < 0.001) 4
• Total sleep time increased by 27.7 minutes (single dose) and 37.9 minutes (Day 5) 4
• Latency to persistent sleep decreased by -18.8 minutes (single dose) and -29.9 minutes (Day 5) 4

Theoretical advantages of OX2-selective antagonists include potentially more balanced REM/NREM sleep and lower narcoleptic/cataplectic risk compared to dual antagonists 5. However, clinical data remain limited, with seltorexant still in Phase II/III trials 5.

Safety Considerations

Lemborexant vs. Daridorexant Safety Profile

• Daridorexant showed higher rates of treatment-emergent adverse events (TEAEs) compared to placebo (RR 1.16; 95% CI: 1.03-1.29), particularly at 25 mg dose 2
• Lemborexant showed no significant difference in overall TEAE rates versus placebo (RR 1.21; 95% CI: 0.98-1.50) 2
• However, lemborexant carried significantly higher risk of somnolence (RR 5.62; 95% CI: 2.92-10.83) compared to daridorexant (RR 1.55; 95% CI: 0.86-2.81) 2

Suvorexant Safety

• Overall adverse event frequency not significantly increased versus placebo 1
• Daytime somnolence increased in dose-dependent fashion: 3.4-8.4% with 15/20 mg doses versus placebo 1
• No evidence of withdrawal symptoms or daytime residual effects 1
• FDA warnings include cognitive/behavioral changes, complex sleep behaviors, and sleep paralysis 1

Clinical Algorithm for Selection

For sleep maintenance insomnia (primary concern: WASO):

• First choice: Lemborexant 10 mg provides greatest WASO reduction 2, 3
• Alternative: Suvorexant 20/15 mg if long-term treatment planned 3
• Caution: Monitor for daytime somnolence with lemborexant 2

For balanced sleep onset and maintenance:

• Consider suvorexant 20 mg, which showed clinically significant reduction in sleep latency (22.3 minutes) in addition to WASO benefits 1

For patients concerned about daytime sedation:

• Daridorexant may have lower somnolence risk but provides less robust WASO improvement 2

Important Caveats

• All AASM recommendations for orexin antagonists are WEAK due to low-quality evidence, imprecision, and publication bias 1
• The 2017 AASM guideline predates approval of lemborexant and daridorexant, limiting direct guideline comparison 1
• DORAs primarily promote REM sleep with minimal effects on slow-wave sleep; clinical significance of this pattern remains unclear 5
• Sleep-onset REM (SOREM) documented with DORAs may be undesirable, particularly in elderly or narcoleptic patients 5
• Long-term safety data beyond brief treatment periods remain limited for all orexin antagonists 1